Oral (non-peptide) GLP-1 receptor agonist · Evidence-led, sources cited
Orforglipron (Orforglipron)
Investigational — NOT yet licensed or available in the UK. Coverage here is educational, on the published research only.
How it works
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist in late-stage development — notable because it's a pill rather than an injection.
Published dosing
There is no UK-licensed dosing — it is not approved. We do not provide dosing for unlicensed or investigational products.
Common side effects
Trial reports describe gastrointestinal effects consistent with the GLP-1 class. This is research-stage information only.
What the evidence shows
Phase 3 results have been reported in the literature and at conferences; UK availability would depend on regulatory approval.